Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era

British Journal of Haematology

Volumn 172, Issue 5, 2016, Pages 724-734

  Nastoupil, Loretta J ^a   Sinha, Rajni ^b   Byrtek, Michelle ^c   Ziemiecki, Ryan ^d   Zhou, Xiaolei ^d   Taylor, Michael ^c   Friedberg, Jonathan W ^e   Link, Brian K ^f   Cerhan, James R ^g   Dawson, Keith ^c   Flowers, Christopher R ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University Oncology and Hematology Associates   (United States)

^c GENENTECH INC   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g MAYO CLINIC   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

Chemotherapy; Immunotherapy; Non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT PLANNING; WATCHFUL WAITING; CLINICAL TRIAL; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84958855830     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13895     Document Type: Article

References (20)

1. Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Vaughan Hudson, G. & Linch, D.C.; British National Lymphoma Investigation. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. The Lancet, 362, 516-522.
2. Ardeshna, K.M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C.F., Miall, F., Cunningham, D., Davies, J., Jack, A., Stephens, R., Walewski, J., Ferhanoglu, B., Bradstock, K. & Linch, D.C. (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. The Lancet Oncoogy, 15, 424-435.
3. Bachy, E., Houot, R., Morschhauser, F., Sonet, A., Brice, P., Belhadj, K., Cartron, G., Audhuy, B., Fermé, C., Feugier, P., Sebban, C., Delwail, V., Maisonneuve, H., Le Gouill, S., Lefort, S., Brousse, N., Foussard, C. & Salles, G.; Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica, 98, 1107-1114.
4. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Céligny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 1110-1117.
5. D'Agostino, R.B. Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17, 2265-2281.
6. El-Galaly, T.C., Bilgrau, A.E., de Nully Brown, P., Mylam, K.J., Ahmad, S.A., Pedersen, L.M., Gang, A.O., Bentzen, H.H., Juul, M.B., Bergmann, O.J., Pedersen, R.S., Nielsen, B.J., Johnsen, H.E., Dybkaer, K., Bøgsted, M. & Hutchings, M. (2015) A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. British Journal of Haematology, 169, 435-444.
7. Friedberg, J.W., Taylor, M.D., Cerhan, J.R., Flowers, C.R., Dillon, H., Farber, C.M., Rogers, E.S., Hainsworth, J.D., Wong, E.K., Vose, J.M., Zelenetz, A.D. & Link, B.K. (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology, 27, 1202-1208.
8. Gallagher, C.J., Gregory, W.M., Jones, A.E., Stansfeld, A.G., Richards, M.A., Dhaliwal, H.S., Malpas, J.S. & Lister, T.A. (1986) Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology, 4, 1470-1480.
9. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dölken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M. & vonGrünhagen, U.; East German Study Group Hematology and Oncology Study. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 1986-1992.
10. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
11. Hochster, H., Weller, E., Gascoyne, R.D., Habermann, T.M., Gordon, L.I., Ryan, T., Zhang, L., Colocci, N., Frankel, S. & Horning, S.J. (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. Journal of Clinical Oncology, 27, 1607-1614.
12. Horning, S.J., Hoppe, R.T., Kaplan, H.S. & Rosenberg, S.A. (1981) Female reproductive potential after treatment for Hodgkin's disease. The New England Journal of Medicine, 304, 1377-1382.
13. Kahl, B.S., Hong, F., Williams, M.E., Gascoyne, R.D., Wagner, L.I., Krauss, J.C., Habermann, T.M., Swinnen, L.J., Schuster, S.J., Peterson, C.G., Sborov, M.D., Martin, S.E., Weiss, M., Ehmann, W.C. & Horning, S.J. (2014) Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. Journal of Clinical Oncology, 32, 3096-3102.
14. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
15. Nastoupil, L.J., Sinha, R., Byrtek, M., Ziemiecki, R., Taylor, M., Friedberg, J.W., Koff, J.L., Link, B.K., Cerhan, J.R., Dawson, K.L. & Flowers, C.R. (2015) Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leukemia & Lymphoma, 56, 1295-1302.
16. Portlock, C.S. & Rosenberg, S.A. (1979) No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Annals of Internal Medicine, 90, 10-13.
17. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89, 3909-3918.
18. Wagner, L.I., Zhao, F., Hong, F., Williams, M.E., Gascoyne, R.D., Krauss, J.C., Advani, R.H., Go, R.S., Habermann, T.M., Leach, J.W., O'Connor, B., Schuster, S.J., Cella, D., Horning, S.J. & Kahl, B.S. (2015) Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology, 33, 740-748.
19. Wagner-Johnston, N.D., Link, B.K., Byrtek, M., Dawson, K.L., Hainsworth, J., Flowers, C.R., Friedberg, J.W. & Bartlett, N.L. (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood, 126, 851-857.
20. Young, R.C., Longo, D.L., Glatstein, E., Ihde, D.C., Jaffe, E.S. & DeVita, V.T. Jr (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars in Hematology, 25, 11-16.